Background: Atrial arrhythmias are present in up to 20% of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Catheter ablation (CA) is an effective treatment for atrial arrhythmias in the general population. Data regarding CA for atrial arrhythmias in ARVC are scarce. Objective: To assess the safety and efficacy of CA for atrial arrhythmias in patients with ARVC. Methods: In this international collaborative effort, all patients with a definite diagnosis of ARVC undergoing CA for atrial fibrillation (AF), focal atrial tachycardia (AT), or cavotricuspid isthmus (CTI)‐dependent atrial flutter (AFl) were extracted from twelve ARVC registries. Demographic, periprocedural, and long‐term arrhythmic outcome data were collected. Results: Thirty‐seven patients were enrolled in the study (age 50.2 ± 16.6 years, male 84%, CHA2DS2VASc 1 (1,2), HAS‐BLED 0 (0–2)). The arrhythmia leading to CA was AF in 23 (62%), focal left AT in 5 (14%), and CTI‐dependent AFl in 9 (24%). Acute procedural success was achieved in all procedures but one (n = 1 focal left AT; 97% acute success). The median follow‐up period was 27 (13–67) months, and 96%, 74%, and 61% of patients undergoing AF ablation were free from any atrial arrhythmia recurrence after a single procedure at 6 months, 12 months, and last follow‐up, respectively. After focal AT ablation, freedom from atrial arrhythmia recurrence was 80%, 80%, and 60% at 6 months, 12 months, and last follow‐up, respectively. All patients undergoing CTI ablation were free from atrial arrhythmia recurrences at 6 months, with 89% single‐procedural arrhythmic freedom at last follow‐up. One major complication (2.7%; PV stenosis requiring PV stenting) occurred. Conclusions: CA is safe and effective in managing atrial arrhythmias in patients with ARVC, with success rates comparable to the general population.

Efficacy of catheter ablation for atrial arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy—a multicenter study / A. Gasperetti, C.A. James, L. Chen, N. Schenker, M. Casella, S. Kany, S. Mathew, P. Compagnucci, A. Mussigbrodt, H.K. Jensen, A. Svensson, S. Costa, G.B. Forleo, P.G. Platonov, C. Tondo, J.-. Song, A.D. Russo, F. Ruschitzka, C. Brunckhorst, H. Calkins, F. Duru, A.M. Saguner. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 10:21(2021), pp. 4962.1-4962.11. [10.3390/jcm10214962]

Efficacy of catheter ablation for atrial arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy—a multicenter study

A. Gasperetti
;
M. Casella;C. Tondo;
2021

Abstract

Background: Atrial arrhythmias are present in up to 20% of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Catheter ablation (CA) is an effective treatment for atrial arrhythmias in the general population. Data regarding CA for atrial arrhythmias in ARVC are scarce. Objective: To assess the safety and efficacy of CA for atrial arrhythmias in patients with ARVC. Methods: In this international collaborative effort, all patients with a definite diagnosis of ARVC undergoing CA for atrial fibrillation (AF), focal atrial tachycardia (AT), or cavotricuspid isthmus (CTI)‐dependent atrial flutter (AFl) were extracted from twelve ARVC registries. Demographic, periprocedural, and long‐term arrhythmic outcome data were collected. Results: Thirty‐seven patients were enrolled in the study (age 50.2 ± 16.6 years, male 84%, CHA2DS2VASc 1 (1,2), HAS‐BLED 0 (0–2)). The arrhythmia leading to CA was AF in 23 (62%), focal left AT in 5 (14%), and CTI‐dependent AFl in 9 (24%). Acute procedural success was achieved in all procedures but one (n = 1 focal left AT; 97% acute success). The median follow‐up period was 27 (13–67) months, and 96%, 74%, and 61% of patients undergoing AF ablation were free from any atrial arrhythmia recurrence after a single procedure at 6 months, 12 months, and last follow‐up, respectively. After focal AT ablation, freedom from atrial arrhythmia recurrence was 80%, 80%, and 60% at 6 months, 12 months, and last follow‐up, respectively. All patients undergoing CTI ablation were free from atrial arrhythmia recurrences at 6 months, with 89% single‐procedural arrhythmic freedom at last follow‐up. One major complication (2.7%; PV stenosis requiring PV stenting) occurred. Conclusions: CA is safe and effective in managing atrial arrhythmias in patients with ARVC, with success rates comparable to the general population.
Ablation in special populations; Arrhythmogenic right ventricular cardiomyopathy; Atrial fibrillation; Atrial flutter; Pulmonary vein isolation
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
Efficacy.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 427.8 kB
Formato Adobe PDF
427.8 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/889703
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact